Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
Twenty-one patients with cystic fibrosis and chronic Pseudomonas lung infection were treated at random with ceftazidime, 150 mg/kg/day, or with piperacillin, 300 mg/kg/day, and tobramycin, 10 and more mg/kg/day for 14 days. On admission and at discharge, body weight, erythrocyte sedimentation rate, white blood cell count, and differential were determined. Pulmonary function analysis and chest X-rays were also obtained on both occasions as was sputum bacteriology. After hospitalization, the patients were followed in the outpatient department for 14-26 months. Both treatments were associated with significant improvement in most of the parameters that were studied, but neither treatment was superior.
De Boeck
K
K
Department of Pediatrics, UZ Gasthuisberg, Leuven, Belgium.
Smet
M
M
Eggermont
E
E
D002442:Ceftazidime / Q000627:therapeutic use*; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications*; D004338:Drug Combinations; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008171:Lung Diseases / Q000097:blood / Q000188:drug therapy*; D009504:Neutrophils / Q000166:cytology; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000097:blood / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D011897:Random Allocation; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*; D014797:Vital Capacity / Q000187:drug effects
D004338:Drug Combinations; D002442:Ceftazidime; D014031:Tobramycin; D010878:Piperacillin